Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Eli Lilly and Company
Stemline Therapeutics, Inc.
Bristol-Myers Squibb
Eli Lilly and Company
Inhibrx Biosciences, Inc
Pathos AI, Inc.
Eli Lilly and Company
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Novartis
Thomas Jefferson University
In8bio Inc.